| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2100258 | Best Practice & Research Clinical Haematology | 2011 | 9 Pages |
Abstract
Despite advancements in the treatment of follicular lymphoma (FL), curative therapy remains an elusive unmet medical need. Improvements in progression-free survival result in new logistical and financial challenges to clinical investigation and drug development in this indolent disease. Surrogate endpoints that utilize imaging and sensitive markers of treatment effect may serve to address this problem. Additionally, alternative trial designs may help to bypass some of the logistical hurdles.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Gregg Fine, Sandra Horning,